SCOPUS 정보 검색 플랫폼

Nature Biotechnology

Volumn 29, Issue 10, 2011, Pages 867-870

A methodological framework to enhance the clinical success of cancer immunotherapy

(4) Hoos, Axel a,b Britten, Cedrik M c,d,e Huber, Christoph e,f O'Donnell Tormey, Jill b,g

a BRISTOL MYERS SQUIBB (United States)

b Cancer Immunotherapy Consortium (CIC) (United States)

c JOHANNES GUTENBERG UNIVERSITY (Germany)

d Ribological GmbH (Germany)

e Association for Cancer Immunotherapy (CIMT) (Germany)

f Center for Translational Oncology and Immunology (TRON) (Germany)

g Cancer Research Institute (CRI) (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; IPILIMUMAB; PROVENGE; TICILIMUMAB;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CLINICAL PROTOCOL; DEATH; DRUG APPROVAL; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GOOD CLINICAL PRACTICE; HAZARD RATIO; HUMAN; IMMUNE RESPONSE; LETTER; MAJOR CLINICAL STUDY; MELANOMA; METHODOLOGY; ONCOLOGY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RISK REDUCTION; TREATMENT RESPONSE; TUMOR IMMUNOLOGY; VACCINATION;

CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; GUIDELINES AS TOPIC; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PUBLICATIONS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80054746895 PISSN: 10870156 EISSN: 15461696 Source Type: Journal
DOI: 10.1038/nbt.2000 Document Type: Letter

Times cited : (56)

References (19)

1
- 77955066199
- Kantoff, P.W. et al. N. Engl. J. Med. 363, 411-422 (2010
- (2010) N. Engl. J. Med. , vol.363 , pp. 411-422
- Kantoff, P.W.¹

2
- 77954801079
- Hodi, F.S. et al. N. Engl. J. Med. 363, 711-723 (2010
- (2010) N. Engl. J. Med. , vol.363 , pp. 711-723
- Hodi, F.S.¹

3
- 59849122181
- Goldman, B. & DeFrancesco, L. Nat. Biotechnol. 27, 129-139 (2009
- (2009) Nat. Biotechnol. , vol.27 , pp. 129-139
- Goldman, B.¹ DeFrancesco, L.²

4
- 33845993628
- Hoos, A. et al. J. Immunother. 30, 1-15 (2007
- (2007) J. Immunother. , vol.30 , pp. 1-15
- Hoos, A.¹

5
- 37349020262
- Janetzki, S. et al. Cancer Immunol. Immunother. 57, 303-315 (2008
- (2008) Cancer Immunol. Immunother. , vol.57 , pp. 303-315
- Janetzki, S.¹

6
- 68549133403
- Britten, C.M. et al. Cancer Immunol. Immunother. 58, 1701-1713 (2009
- (2009) Cancer Immunol. Immunother. , vol.58 , pp. 1701-1713
- Britten, C.M.¹

7
- 77957273591
- Hoos, A. et al. J. Natl. Cancer Inst. 102, 1388-1397 (2010
- (2010) J. Natl. Cancer Inst. , vol.102 , pp. 1388-1397
- Hoos, A.¹

8
- 73149092567
- Wolchok, J.D. et al. Clin. Cancer Res. 15, 7412-7420 (2009
- (2009) Clin. Cancer Res. , vol.15 , pp. 7412-7420
- Wolchok, J.D.¹

9
- 70349833381
- Janetzki, S. et al. Immunity 31, 527-528 (2009
- (2009) Immunity , vol.31 , pp. 527-528
- Janetzki, S.¹

10
- 84857111080
- Guidance for industry: Clinical considerations for therapeutic cancer vaccines. (US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, September
- Guidance for industry: Clinical considerations for therapeutic cancer vaccines. (US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, September 2009). http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/default.htm
- (2009)

11
- 80054743834
- European Medicines Agency. Concept paper on the need to revise the guidelines on the evaluation of anticancer medicinal products in man. 22 July 2010. EMA/CHMP/EWP/433478/2010.
- European Medicines Agency. Concept paper on the need to revise the guidelines on the evaluation of anticancer medicinal products in man. 22 July 2010. EMA/CHMP/EWP/433478/2010.

12
- 34748918373
- Finke, L.H. et al. Vaccine 25, B97-B109 (2007
- (2007) Vaccine , vol.25
- Finke, L.H.¹

13
- 78449258549
- Hoos, A. et al. Semin. Oncol. 37, 533-546 (2010
- (2010) Semin. Oncol. , vol.37 , pp. 533-546
- Hoos, A.¹

14
- 80054760104
- Evaluation of baseline serum C-reactive protein and benefit from tremelimumab compared to chemotherapy in firstline melanoma
- Abstract no. 2609, presented at the, Chicago, IL, June 4-8
- Marshall, M., Ribas, A. & Huang, B. Evaluation of baseline serum C-reactive protein and benefit from tremelimumab compared to chemotherapy in firstline melanoma. Abstract no. 2609, presented at the 2010 annual meeting of the American Society Clinical Oncology, Chicago, IL, June 4-8, 2010.
- (2010) 2010 annual meeting of the American Society Clinical Oncology
- Marshall, M.¹ Ribas, A.² Huang, B.³

15
- 79959772576
- Robert, C. et al. N. Engl. J. Med. 364, 2517-2526 (2011
- (2011) N. Engl. J. Med. , vol.364 , pp. 2517-2526
- Robert, C.¹

16
- 45749118607
- Taylor, C.F. et al. Nat. Biotechnol. 26, 889-896 (2008
- (2008) Nat. Biotechnol. , vol.26 , pp. 889-896
- Taylor, C.F.¹

17
- 45549092607
- Finn, O.J. N. Engl. J. Med. 358, 2704-2715 (2008
- (2008) N. Engl. J. Med. , vol.358 , pp. 2704-2715
- Finn, O.J.¹

18
- 79953151458
- Schreiber, R., Old, L.J. & Smyth, M.J. Science 331, 1565-1570 (2011
- (2011) Science , vol.331 , pp. 1565-1570
- Schreiber, R.¹ Old, L.J.² Smyth, M.J.³

19
- 79952390627
- Zitvogel, L., Kepp, O. & Kroemer, G. Nat. Rev. Clin. Oncol. 8, 151-160 (2011).
- (2011) Nat. Rev. Clin. Oncol. , vol.8 , pp. 151-160
- Zitvogel, L.¹ Kepp, O.² Kroemer, G.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.